Authors

• Binghe Xu (ORCID: https://orcid.org/0000-0003-4195-337X)
• Arlene Reisman
• Cheng-Yu Huang (ORCID: https://orcid.org/0000-0001-9070-2062)
• Jiayun Shen (ORCID: https://orcid.org/0000-0001-5011-4303)
• Kunwei Shen (ORCID: https://orcid.org/0000-0002-1961-8666)
• Tao Sun (ORCID: https://orcid.org/0000-0001-5931-386X)
• Roger K.C. Ngan (ORCID: https://orcid.org/0000-0003-0755-3604)
• Edward Broughton (ORCID: https://orcid.org/0000-0001-8621-7267)
• Xichun Hu (ORCID: https://orcid.org/0000-0002-9892-699X)
• Virote Sriuranpong
• Yee Hong Chia
• Wei Li (ORCID: https://orcid.org/0009-0008-0018-036X)
• Huadong Zhao

Institutions

• Chulalongkorn University (TH)
• Chinese University of Hong Kong (HK)
• Pfizer (United States) (US)
• Shanghai Jiao Tong University (CN)
• Jilin University (CN)
• Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
• Ruijin Hospital (CN)
• King Chulalongkorn Memorial Hospital (TH)
• Tan Tock Seng Hospital (SG)
• Fudan University Shanghai Cancer Center (CN)
• First Hospital of Jilin University (CN)
• National Taiwan University Hospital (TW)
• Pfizer (China) (CN)
• Liaoning Cancer Hospital & Institute (CN)
• University of Hong Kong (HK)
• China Medical University (CN)

Publication Details

Journal

Chinese Medical Journal

Published

2024-12-19

DOI

https://doi.org/10.1097/cm9.0000000000003122

Citations

1

Primary Topic

Advanced Breast Cancer Therapies

Type

article

Field-Weighted Citation Impact

0.42